Search Results - "Savic, R M"

Diagnosing Model Diagnostics by Karlsson, M O, Savic, R M

“…Conclusions from clinical trial results that are derived from model‐based analyses rely on the model adequately describing the underlying system. The…”
Get full text

A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials by Hills, N K, Lyimo, J, Nahid, P, Savic, R M, Lienhardt, C, Phillips, P P J

“…Safe, more efficacious treatments are needed to address the considerable morbidity and mortality associated with pulmonary tuberculosis (TB). However, the…”
Get full text

A comparison of clinical development pathways to advance tuberculosis regimen development by Chang, V, Phillips, P P J, Imperial, M Z, Nahid, P, Savic, R M

“…Current tuberculosis (TB) regimen development pathways are slow and in urgent need of innovation. We investigated novel phase IIc and seamless phase II/III…”
Get full text

Importance of Drug Pharmacokinetics at the Site of Action by Rizk, ML, Zou, L, Savic, RM, Dooley, KE

“…CSF as well as variability in penetration of drugs to the brain and CSF related to inflammation and breakdown of vascular integrity, the dynamics of drug…”
Get full text

Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure–response relations from two phase II clinical trials by Savic, RM, Weiner, M, MacKenzie, WR, Engle, M, Whitworth, WC, Johnson, JL, Nsubuga, P, Nahid, P, Nguyen, NV, Peloquin, CA, Dooley, KE, Dorman, SE

“…Rifapentine is a highly active antituberculosis antibiotic with treatment‐shortening potential; however, exposure–response relations and the dose needed for…”
Get full text

Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children by Savic, RM, Ruslami, R, Hibma, JE, Hesseling, A, Ramachandran, G, Ganiem, AR, Swaminathan, S, McIlleron, H, Gupta, A, Thakur, K, van Crevel, R, Aarnoutse, R, Dooley, KE

“…Pediatric tuberculous meningitis (TBM) is a highly morbid, often fatal disease. Standard treatment includes isoniazid, rifampin, pyrazinamide, and ethambutol…”
Get full text

A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin by Goswami, S, Yee, SW, Xu, F, Sridhar, SB, Mosley, JD, Takahashi, A, Kubo, M, Maeda, S, Davis, RL, Roden, DM, Hedderson, MM, Giacomini, KM, Savic, RM

“…One‐third of type‐2 diabetic patients respond poorly to metformin. Despite extensive research, the impact of genetic and nongenetic factors on long‐term…”
Get full text

Effect of Adherence as Measured by MEMS, Ritonavir Boosting, and CYP3A5 Genotype on Atazanavir Pharmacokinetics in Treatment-Naive HIV-Infected Patients by Savic, R M, Barrail-Tran, A, Duval, X, Nembot, G, Panhard, X, Descamps, D, Verstuyft, C, Vrijens, B, Taburet, A-M, Goujard, C, Mentré, F

“…We investigated population pharmacokinetics and pharmacogenetics of ritonavir‐boosted atazanavir (ATV), using drug intake times exactly recorded by the…”
Get full text

Genetic Variants in Transcription Factors Are Associated With the Pharmacokinetics and Pharmacodynamics of Metformin by Goswami, S, Yee, S W, Stocker, S, Mosley, J D, Kubo, M, Castro, R, Mefford, J A, Wen, C, Liang, X, Witte, J, Brett, C, Maeda, S, Simpson, M D, Hedderson, M M, Davis, R L, Roden, D M, Giacomini, K M, Savic, R M

“…One‐third of type 2 diabetes patients do not respond to metformin. Genetic variants in metformin transporters have been extensively studied as a likely…”
Get full text

New Paradigm for Translational Modeling to Predict Long‐term Tuberculosis Treatment Response by Bartelink, IH, Zhang, N, Keizer, RJ, Strydom, N, Converse, PJ, Dooley, KE, Nuermberger, EL, Savic, RM

“…Disappointing results of recent tuberculosis chemotherapy trials suggest that knowledge gained from preclinical investigations was not utilized to maximal…”
Get full text

Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis by Imperial, Marjorie Z, Nedelman, Jerry R, Conradie, Francesca, Savic, R M

“…Abstract Background We evaluated Nix-TB trial data (NCT02333799, N = 109) to provide dosing recommendations to potentially minimize linezolid toxicity in…”
Get full text

Responding to the post-pandemic crisis: post-exposure prophylaxis for TB by Heffernan, C., Savić, R. M., Long, R. G., Raviglione, M. C., Ferrara, G.

Get full text

Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine Exposure by Jayakumar, A, Savic, R M, Everett, C K, Benator, D, Alland, D, Heilig, C M, Weiner, M, Friedrich, S O, Martinson, N A, Kerrigan, A, Zamudio, C, Goldberg, S V, Whitworth, W C, Davis, J L, Nahid, P

“…The Xpert MTB/RIF assay is both sensitive and specific as a diagnostic test. Xpert also reports quantitative output in cycle threshold (C ) values, which may…”
Get full text

Clinical standards for the dosing and management of TB drugs by Alffenaar, J. W. C., Stocker, S. L., Forsman, L. Davies, Garcia-Prats, A., Heysell, S. K., Aarnoutse, R. E., Akkerman, O. W., Aleksa, A., van Altena, R., de Oñata, W. Arrazola, Bhavani, P. K., van't Boveneind-Vrubleuskaya, N., Carvalho, A. C. C., Centis, R., Chakaya, J. M., Cirillo, D. M., Cho, J. G., D´Ambrosio, L., Dalcolmo, M. P., Denti, P., Dheda, K., Fox, G. J., Hesseling, A. C., Kim, H. Y., Köser, C. U., Marais, B. J., Margineanu, I., Märtson, A. G., Torrico, M. Munoz, Nataprawira, H. M., Ong, C. W. M., Otto-Knapp, R., Peloquin, C. A., Silva, D. R., Ruslami, R., Santoso, P., Savic, R. M., Singla, R., Svensson, E. M., Skrahina, A., van Soolingen, D., Srivastava, S., Tadolini, M., Tiberi, S., Thomas, T. A., Udwadia, Z. F., Vu, D. H., Zhang, W., Mpagama, S. G., Schön, T., Migliori, G. B.

“…BACKGROUND: Optimal drug dosing is important to ensure adequate response to treatment, prevent development of drug resistance and reduce drug toxicity. The aim…”
Get full text

Impact of Adherence and Anthropometric Characteristics on Nevirapine Pharmacokinetics and Exposure Among HIV-Infected Kenyan Children by Vreeman, Rachel C, Nyandiko, Winstone M, Liechty, Edward A, Busakhala, Naftali, Bartelink, Imke H, Savic, Rada M, Scanlon, Michael L, Ayaya, Samual O, Blaschke, Terry F

“…BACKGROUND:There are insufficient data on pediatric antiretroviral therapy (ART) pharmacokinetics (PK), particularly for children in low- and middle-income…”
Get full text

Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation by Bognàr, Tim, Bartelink, Imke H., Egberts, Toine C.G., Rademaker, Carin M.A., Versluys, A. Birgitta, Slatter, Mary A., Kletzel, Morris, Nath, Christa E., Cuvelier, Geoffrey D.E, Savic, Rada M., Dvorak, Christopher, Long-Boyle, Janel R., Cowan, Morton J., Bittencourt, Henrique, Bredius, Robbert G.M., Güngör, Tayfun, Shaw, Peter J., Ansari, Marc, Hassan, Moustapha, Krajinovic, Maja, Hempel, Georg, Marktel, Sarah, Chiesa, Robert, Théoret, Yves, Lund, Troy, Orchard, Paul J., Wynn, Robert F., Boelens, Jaap Jan, Lalmohamed, Arief

“…Intravenous busulfan is widely used as part of myeloablative conditioning regimens in children and young adults undergoing allogeneic hematopoietic cell…”
Get full text

Effect of heating and cooling on interaction of lysine-rich histones with deoxyribonucleic acid by Cvetković, M D, Savić, R M

Get full text

Busulfan Exposure Predicts Event Free Survival and Toxicity after Hematopoietic Cell Transplantation in Children And Young Adults: A Multicenter Retrospective Cohort Analysis by Bartelink, IH, Lalmohamed, A, van Reij, EM, Dvorak, CC, Savic, RM, Zwaveling, J, Bredius, RG, Egberts, AC, Bierings, M, Kletzel, M, Shaw, PJ, Nath, CE, Hempel, G, Ansari, M, Krajinovic, M, Theoret, Y, Duval, M, Keizer, RJ, Bittencourt, H, Hassan, M, Gungor, T, Wynn, RF, Veys, P, Cuvelier, GD, Marktel, S, Chiesa, R, Cowan, MJ, Slatter, MA, Stricherz, MK, Jennissen, C, Long-Boyle, JR, Boelens, JJ

Get full text

Application of population pharmacokinetics to cladribine by Lindemalm, Synnöve, Savic, Radojka M, Karlsson, Mats O, Juliusson, Gunnar, Liliemark, Jan, Albertioni, Freidoun

“…The nucleoside analog cladribine is used for the treatment of a variety of indolent B- and T-cell lymphoid malignancies. The primary aim of the study was to…”
Get full text